Mild Cognitive Impairment: An uncertain diagnosis or a diagnostic uncertainty?
A panel discussion sponsored by BiogenThere is significant heterogeneity in terms of the usefulness of a mild cognitive impairment (MCI) diagnosis, and although there is increasing scientific evidence around MCI being an appropriate and useful diagnosis, there is still some debate in the scientific community on this topic with clinical arguments on both sides.
The objective of this symposium is to provide a platform for scientific discussion on the topic and to cover the issues surrounding this subject so the audience can hear different perspectives and make an informed opinion on the topic.
This symposium has been developed and funded by
BiogenAbout Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.
One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and is focused on potential therapies in neuromuscular, neurodegenerative, and ophthalmology disease areas.
Biogen also believes that biosimilars, and their associated cost-savings, are central to safeguarding future healthcare.
To learn more, please visit
www.biogen.uk.com, www.biogen.ie